{"id":"NCT01034462","sponsor":"Forest Laboratories","briefTitle":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","officialTitle":"A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2011-12","completion":"2011-12","firstPosted":"2009-12-17","resultsPosted":"2013-10-25","lastUpdate":"2013-10-25"},"enrollment":442,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Levomilnacipran ER","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder","primaryOutcome":{"measure":"Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","timeFrame":"From Baseline to Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-12.2,"sd":0.78},{"arm":"Levomilnacipran ER","deltaMin":-15.3,"sd":0.79}],"pValues":[{"comp":"OG000","p":"0.0051"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":23,"countries":["United States"]},"refs":{"pmids":["27861191","26644957","24172209"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":217},"commonTop":["Headache","Nausea","Dry mouth","Dizziness","Constipation"]}}